A randomized and comparative study of ipragliflozin and sitagliptin in patients with type 2 diabetes

INTERVENTION: Orally administration of 50 mg sitagliptin once a day, pre or post breakfast for 12 weeks Orally administration of 50 mg ipragliflozin once a day, pre or post breakfast for 12 weeks CONDITION: Type 2 diabetes PRIMARY OUTCOME: Proportion of patients for whom HbA1c decreases 0.5% or more and not increase in weight at 12 weeks after initiation SECONDARY OUTCOME: Change and percent change in following items from baseline to 12 weeks; 1) Serum insulin (immunoreactive insulin); 2) HOMA‐IR; 3) HOMA‐beta; 4) Serum lipids; 5) LPL (quantitative determination); 6) FFA (free fatty acids); 7) FABP (fatty acid binding protein); 8) P/I ratio (proinsulin/insulin ratio); 9) Serum glucagon; 10) Serum ketone body; 11) Body composition INCLUSION CRITERIA: 1) Aged from 20 to 75 years at providing consent 2) HbA1c >= 6.5% 3) BMI >= 23 kg/m2 4) Provide written informed consent